Market closedNon-fractional
Trevi Therapeutics/TRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Ticker
TRVI
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
New Haven, United States
Employees
25
Website
www.trevitherapeutics.com
TRVI Metrics
BasicAdvanced
$223M
Market cap
-
P/E ratio
-$0.34
EPS
0.91
Beta
-
Dividend rate
Price and volume
Market cap
$223M
Beta
0.91
Financial strength
Current ratio
14.55
Quick ratio
13.802
Long term debt to equity
1.312
Total debt to equity
1.757
Interest coverage (TTM)
-237.68%
Management effectiveness
Return on assets (TTM)
-24.56%
Return on equity (TTM)
-38.57%
Valuation
Price to book
3.04
Price to tangible book (TTM)
3.04
Price to free cash flow (TTM)
-9.238
Growth
Earnings per share change (TTM)
-2.36%
3-year earnings per share growth (CAGR)
-42.40%
What the Analysts think about TRVI
Analyst Ratings
Majority rating from 6 analysts.
TRVI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
39.74%
Profit margin
0.00%
NaN%
TRVI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.08
-$0.08
-$0.11
-
Expected
-$0.09
-$0.09
-$0.09
-$0.09
-$0.11
Surprise
-17.65%
-12.73%
-12.73%
25.00%
-
TRVI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $223M as of July 27, 2024.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of July 27, 2024.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Trevi Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.